Zacks Investment Research on MSN1d
Hims & Hers Stock Gains 8.6% in Three Months: How to Play It?Hims & Hers Health, Inc.’s HIMS investors have been experiencing some short-term gains from the stock of late. Shares of the ...
Four-star-rated analyst Daniel Grosslight at Citi reiterated his Sell rating on Hims & Hers Health (HIMS) stock yesterday, ...
Hims & Hers Health ( HIMS -12.79%) stock took a tumble Thursday morning, falling 9.2% through 11:40 a.m. ET on some ...
Hims & Hers is shutting down Apostrophe, the skincare company it acquired in 2021, after a tumultuous month for the public ...
Hims & Hers Health (HIMS) has disclosed plans to shut down Apostrophe, its acne treatment business. This change is part of ...
The rapid rise of GLP-1 weight-loss drugs has come with a raucous side show—a wave of copycat drugs unbound by drug patents.
Hims & Hers saw a massive YTD surge, but FDA news led to a pullback. Find out why HIMS stock is still undervalued and why ...
Hims & Hers (NYSE: HIMS) stock is down 50% from its peak earlier this year, but the drop in shares hasn't been driven by deteriorating operations. In fact, the company is growing as fast as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback